Soligenix | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.58, beating the estimate of USD -0.63.

EBIT: As of FY2025 Q3, the actual value is USD -2.633 M.

Specialized BioTherapeutics Segment

• Research and Development Expenses: $4,780,375 for the nine months ended September 30, 2025, compared to $1,913,395 for the same period in 2024, representing an increase primarily due to costs associated with the second confirmatory Phase 3 CTCL trial and Phase 2 study in BD.

Public Health Solutions Segment

• Research and Development Expenses: $64,218 for the nine months ended September 30, 2025, compared to $163,361 for the same period in 2024, indicating a decrease.

Corporate

• General and Administrative Expenses: $2,980,613 for the nine months ended September 30, 2025, compared to $3,050,450 for the same period in 2024, showing a slight decrease.

Cash Flow

• Net Cash Flows from Operating Activities: -$7,521,449 for the nine months ended September 30, 2025, compared to -$6,170,761 for the same period in 2024, indicating increased cash usage.
• Net Cash Flows from Financing Activities: $10,231,191 for the nine months ended September 30, 2025, compared to $7,519,211 for the same period in 2024, reflecting increased financing activities.

Future Outlook and Strategy

• Core Business Focus: Continue enrollment and execution of the FLASH2 study for HyBryte™ in CTCL, expand development of synthetic hypericin into psoriasis, and design a second Phase 3 trial for SGX942 in oral mucositis.
• Non-Core Business: Continue development of ThermoVax® technology and pursue business development opportunities, including potential mergers and acquisitions.

Outlook Summary

The company plans to continue its strategic focus on advancing its core product candidates through clinical trials, while also exploring additional funding opportunities and potential partnerships to support its pipeline programs. The company is actively seeking government grants and contracts to sustain its Public Health Solutions segment.